

PrEP and Condom Use in High Risk MSM in the ANRS IPERGAY Trial (Double-blinded phase)

Poster Board Number 887



Auteurs


Luis Sagaon-Teyssier^{1,2,3}, Marie Suzan-Monti^{1,2,3}, Daniela Rojas, Castro⁴, Nolwenn Hall⁵, Catherine Capitant⁶, Christian Chidiac⁷, Cécile Tremblay⁸, Bruno Spire^{1,2,3}, Jean-Michel Molina⁹, ANRS IPERGAY Study Group §

- INSERM, UMR912 «Economics and Social Sciences Applied to Health & Analysis of Medical Information» (SESSTIM), 13006, Marseille, France;
- Aix Marseille University, UMR_S912, IRD, 13006, Marseille, France;
- ORS PACA, Southeastern Health Regional Observatory, 13006, Marseille, France;
- AIDES, MIRE, Paris, France;
- Department of Infectious diseases, CHU de Nantes, France;
- INSERM SC10 US19, Villejuif, France;
- Department of Infectious Diseases, Hôpital de la Croix Rousse, INSERM U1052, Lyon, France;
- Research Center of the Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada;
- Hospital Saint-Louis, Department of Infectious Disease, Assistance Publique Hôpitaux de Paris, Paris, France.

Results : Outcomes

332 participants (out of 400) had anal sex at least once during the double-blinded phase : 49.9% placebo & 52.1% TDF/FTC

- 1115 Questionnaires analyzed for PrEP use
- 1935 Questionnaires analyzed for Condom use




Background and objective

- Men who have sex with men (MSM) constitute a high-risk group in France's HIV epidemic. In the setting of the follow-up in the ANRS IPERGAY PrEP trial.
- Aim: To identify behavioral trajectories over time for PrEP and condom use and to investigate links between these trajectories, using a tailored methodological framework.

Results : Latent multi-trajectory model

Purpose : To identify clusters according to the PrEP and Condom use behavior

FOUR TRAJECTORIES OF PREP USE




Data (double-blinded phase) and Methods

- The trial : ANRS IPERGAY was a randomized double-blind trial of sexual activity-based PrEP in high-risk MSM, assigned to TDF-FTC or placebo.
- Data collection : Online questionnaires collecting sexual behaviour and PrEP adherence data during the most recent episode of sexual intercourse were completed every 2 months.
 - Analyses based on the data of the double-blinded phase
 - TDF/FTC and Placebo arms were pooled


Advantage : Controls observable and unobservable heterogeneity

TWO TRAJECTORIES OF CONDOM USE



JOINT ESTIMATION

Condom use trajectories according to PrEP use trajectories (N=332)



Among High-level condom users (C-HLU) : 78.5% were PrEP-SU/PrEP-HLU
21.5% were PrEP-DU/PrEP-LLU

Among Low-level condom users (C-LLU) : 77% were PrEP-SU/PrEP-HLU, 23% were PrEP-DU/PrEP-LLU (the most-at-risk group).

MULTIVARIATE LOGISTIC ANALYSIS : THE MOST-AT-RISK GROUP=1 VS THE MOST PROTECTED GROUP=0

	OR	P-value
Age (continuous variable)	1.05	<0.001
Education level (ref. ≤ high-school)	1.91	0.02
Known partner (ref. No)	2.09	<0.001
Sexually dissatisfied (ref. No)	2.09	<0.001

A trend appears for participants practicing insertive anal sex (p=0.08)

Conclusion

In the ANRS IPERGAY trial, most high-risk MSM used either PrEP and/or condoms during the most recent anal intercourse. Special attention must be paid to MSM with low condom use who do not compensate by using PrEP, representing 23% among the 332 participants included in this analysis.

Aknowledgements

We would like to thank the study's participants for their time and their dedication to this research for the benefit of their community. We also thank the AIDES community advocacy group and their community peer counselors who made this study possible through continuous interactions with the participants and study staff at study sites and, most importantly, between visits (JM, Le Gall, S. Morel, V. Pechenot, S. Bagge, A. Djessima Taba, M. Danet, K. Moudachirou, B. Dos Santos, J. Lambec, S. Roubay, X. Teruini, N. Dumon, V. Coquelin, P. Brunet, L. Gilly, T. Capitelli, R. Porion, L. Babonnaud, D. Rojas Castro, B. Spire). We thank our community advisory board for its continuous support during the study (S. Karon (secretary), D. Villard (Action Santé Alternative), J.M. Astor (Boucle Rouge), D. Ganaye (Federation LGBT), T. Craig (Act-Up), B. Brive (J'y suis j'y reste), R. Orioli (Les Flamands Roses), M. Vanhede (Solidarité SIDA), H. Baudouin (Sida Info Service), H. Fisher (TRT-S), and the Gay communities in France and Canada (COOSIDA, REZO) who supported this work, Drs S. Becker, P.S. Sow, J. Presley and M. Alkenhad at the Bill and Melinda Gates foundation for fruitful discussions and funding, Dr J.F. Rooney, A. Cheng, H. Jaffe, C. Rabian and P. Petour at

Gilead Sciences for donating study drugs, and members of the Independent data and safety monitoring board for their expertise and guidance (Drs D. Costagliola (Chair), Y. Yazdanpanah, V.K. Nguyen, A.-M. Taburet, and C. Taéron).

§The ANRS IPERGAY study group: J.-M. Molina (coordinator), C. Capitant, B. Spire, G. Pialoux, L. Cotte, I. Charreau, C. Tremblay, J.-M. Le Gall, E. Cua, A. Pasquet, F. Raffi, C. Pintado, C. Chidiac, J. Chas, P. Charbonneau, C. Delaugerre, M. Suzan-Monti, B. Loze, J. Fonsart, G. Peytavin, A. Cheret, J. Timsit, G. Girard, N. Lorenze, M. Préau, J.F. Rooney, M.A. Wainberg, D. Thompson, W. Rozenbaum, V. Doré, L. Marchand, M.-C. Simon, N. Eiten, J.-P. Aboukher, L. Meyer, and J.-F. Delfrassay.

• Participating hospitals and investigators: Paris St-Louis: C. Pintado, B. Loze, C. Delaugerre, P. Charbonneau, C. Gatey, D. Ponscarme, P. Fenot, L. Niedzialski, R. Veron, J. Delgado, E. Dalle, S. Parlier, I. Madelaine, J. Fonsart, M. Danet, N. Mahjoub, N. Mezreb, K. Moudachirou, S. Morel, G. Conort, F. Lorho, M. Meunier, W. Rozenbaum, JM Molina; Paris Tenon: J. Chas, C. Monfort,

J. Foucoin, B. Boissavy, S. Cousseau, S. Huon, M. Danet, A. Djessima, V. Berberi, A. Adda, S. le Nagat, L. Zarka, J. Berdougo, G. Pialoux; Lyon: C. Chidiac, N. Mzoughi, F. Clement, A. Decouty, C. Chapolard, M. Godinot, C. Adouard-grosalafage, J. Koffi, A. Pansu, A. Becker, S. Pailhes, F. Bonnet, F. Jeanblanc, C. Brochier, X. Teruini, S. Roubay, L. Gilly, L. Cotte; Montréal: C. Beauvais, P. Arlotto, C. Fortin, A. Talbot, A. Chamberland, A. McKenzie, M. Blanchette, R. Rousseau, K. Montheuth, D. Thompson, M. Morin, M. Wainberg, C. Tremblay; Nice: C. Etienne, F. Tolonin, S. Breaud, V. Péchenot, S. Bagge, T. Capitelli, PM. Roger, E. Rosenthal, E. Cua; Tourcoing: A. Cheret, P. Cornavin, S. Vandamme, J. Lambec, N. Dumon, O. Leclanche, T. Huleux, R. Bieker, O. Robineau, H. Meliez, H. Bazus, A. Pasquet; Nantes: C. Bernaud, M. Besnier, B. Bonnet, N. Hall, M. Cavellec, H. Hue, L. Larret, M. Colas, R. Choquet, F. Raffi.

• Finally, we would like to thank Jude Sweeney for revising and editing the manuscript.